Published in Nat Rev Microbiol on July 01, 2009
Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature (2014) 5.51
Overdiagnosis of Clostridium difficile Infection in the Molecular Test Era. JAMA Intern Med (2015) 5.04
Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol (2013) 4.34
Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol (2011) 3.81
Comparison of nine commercially available Clostridium difficile toxin detection assays, a real-time PCR assay for C. difficile tcdB, and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxigenic culture methods. J Clin Microbiol (2009) 3.18
Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis. Infect Immun (2011) 2.87
Control of pathogens and pathobionts by the gut microbiota. Nat Immunol (2013) 2.84
Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol (2010) 2.61
Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol (2011) 2.47
Role of the commensal microbiota in normal and pathogenic host immune responses. Cell Host Microbe (2011) 2.46
Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis (2014) 2.41
Interleukin-22 regulates the complement system to promote resistance against pathobionts after pathogen-induced intestinal damage. Immunity (2014) 2.37
Relating the metatranscriptome and metagenome of the human gut. Proc Natl Acad Sci U S A (2014) 2.11
Clinical Clostridium difficile: clonality and pathogenicity locus diversity. PLoS One (2011) 2.04
Microevolutionary analysis of Clostridium difficile genomes to investigate transmission. Genome Biol (2012) 2.04
Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models. J Infect Dis (2011) 1.98
Intestinal colonization resistance. Immunology (2013) 1.85
High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes (2013) 1.85
Clostridium difficile spore biology: sporulation, germination, and spore structural proteins. Trends Microbiol (2014) 1.73
Predictors of severe outcomes associated with Clostridium difficile infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther (2012) 1.67
Innate Immune Defenses Mediated by Two ILC Subsets Are Critical for Protection against Acute Clostridium difficile Infection. Cell Host Microbe (2015) 1.66
Rational design of inhibitors and activity-based probes targeting Clostridium difficile virulence factor TcdB. Chem Biol (2010) 1.60
Clostridium difficile infection after adult autologous stem cell transplantation: a multicenter study of epidemiology and risk factors. Biol Blood Marrow Transplant (2013) 1.58
Bacteriocin production: a probiotic trait? Appl Environ Microbiol (2011) 1.57
Toll-like receptor 5 stimulation protects mice from acute Clostridium difficile colitis. Infect Immun (2011) 1.53
Importance of prophages to evolution and virulence of bacterial pathogens. Virulence (2013) 1.48
Frizzled proteins are colonic epithelial receptors for C. difficile toxin B. Nature (2016) 1.47
Host Biology in Light of the Microbiome: Ten Principles of Holobionts and Hologenomes. PLoS Biol (2015) 1.47
Clostridium difficile infection: guideline-based diagnosis and treatment. Dtsch Arztebl Int (2014) 1.47
Multiple factors modulate biofilm formation by the anaerobic pathogen Clostridium difficile. J Bacteriol (2012) 1.47
Genome-Based Infection Tracking Reveals Dynamics of Clostridium difficile Transmission and Disease Recurrence. Clin Infect Dis (2015) 1.45
Critical role for MyD88-mediated neutrophil recruitment during Clostridium difficile colitis. Infect Immun (2012) 1.43
Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook. Gastroenterology (2015) 1.42
Nfil3 is crucial for development of innate lymphoid cells and host protection against intestinal pathogens. J Exp Med (2014) 1.40
Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulence-associated phenotypes. J Clin Microbiol (2011) 1.37
Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota. J Clin Microbiol (2011) 1.34
Antibiotics, microbiota, and immune defense. Trends Immunol (2012) 1.33
Lipolysis-stimulated lipoprotein receptor (LSR) is the host receptor for the binary toxin Clostridium difficile transferase (CDT). Proc Natl Acad Sci U S A (2011) 1.31
Spores of Clostridium difficile clinical isolates display a diverse germination response to bile salts. PLoS One (2012) 1.31
Cefoperazone-treated mice as an experimental platform to assess differential virulence of Clostridium difficile strains. Gut Microbes (2011) 1.29
From stool transplants to next-generation microbiota therapeutics. Gastroenterology (2014) 1.29
Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease. J Infect Dis (2012) 1.25
Reconsidering the sporulation characteristics of hypervirulent Clostridium difficile BI/NAP1/027. PLoS One (2011) 1.24
Global analysis of the sporulation pathway of Clostridium difficile. PLoS Genet (2013) 1.24
Protective role of commensals against Clostridium difficile infection via an IL-1β-mediated positive-feedback loop. J Immunol (2012) 1.24
Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B. Infect Immun (2011) 1.24
Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review. PLoS One (2014) 1.23
Expanding the repertoire of gene tools for precise manipulation of the Clostridium difficile genome: allelic exchange using pyrE alleles. PLoS One (2013) 1.23
Microbiota-mediated inflammation and antimicrobial defense in the intestine. Annu Rev Immunol (2015) 1.23
Surface layers of Clostridium difficile endospores. J Bacteriol (2011) 1.22
A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection. Infect Immun (2012) 1.22
Clostridium difficile toxins: mediators of inflammation. J Innate Immun (2012) 1.21
Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain. J Biol Chem (2011) 1.19
Clostridium difficile infection: An overview of the disease and its pathogenesis, epidemiology and interventions. Gut Microbes (2010) 1.19
Structural and functional analysis of the CspB protease required for Clostridium spore germination. PLoS Pathog (2013) 1.19
Dynamics and establishment of Clostridium difficile infection in the murine gastrointestinal tract. Infect Immun (2014) 1.18
Anti-infective activities of lactobacillus strains in the human intestinal microbiota: from probiotics to gastrointestinal anti-infectious biotherapeutic agents. Clin Microbiol Rev (2014) 1.17
Clostridium difficile infection. Am J Med Sci (2010) 1.17
In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrob Agents Chemother (2013) 1.17
Adaptive strategies and pathogenesis of Clostridium difficile from in vivo transcriptomics. Infect Immun (2013) 1.17
Proton pump inhibitors affect the gut microbiome. Gut (2015) 1.17
Models for the study of Clostridium difficile infection. Gut Microbes (2012) 1.16
Cross-sectional study reveals high prevalence of Clostridium difficile non-PCR ribotype 078 strains in Australian veal calves at slaughter. Appl Environ Microbiol (2013) 1.15
Fidaxomicin inhibits spore production in Clostridium difficile. Clin Infect Dis (2012) 1.15
The spore differentiation pathway in the enteric pathogen Clostridium difficile. PLoS Genet (2013) 1.14
Clostridium difficile genotypes other than ribotype 078 that are prevalent among human, animal and environmental isolates. BMC Microbiol (2012) 1.14
SpoIVA and SipL are Clostridium difficile spore morphogenetic proteins. J Bacteriol (2013) 1.13
Evaluation of three enzyme immunoassays and a loop-mediated isothermal amplification test for the laboratory diagnosis of Clostridium difficile infection. Eur J Clin Microbiol Infect Dis (2012) 1.12
A genomic signature and the identification of new sporulation genes. J Bacteriol (2013) 1.12
Clostridium difficile isolates resistant to fluoroquinolones in Italy: emergence of PCR ribotype 018. J Clin Microbiol (2010) 1.12
Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. J Med Microbiol (2011) 1.10
Epidemiology of Clostridium difficile infection. J Pharm Pract (2013) 1.10
CAGS Clinical Practice Committee report: the science of Clostridium difficile and surgery. Can J Surg (2013) 1.10
In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species. Antimicrob Agents Chemother (2011) 1.09
Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies. J Infect Dis (2012) 1.09
Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria. Antimicrob Agents Chemother (2012) 1.09
Mutagenic analysis of the Clostridium difficile flagellar proteins, FliC and FliD, and their contribution to virulence in hamsters. Infect Immun (2011) 1.09
Infectious diarrhea: Cellular and molecular mechanisms. Gut Microbes (2010) 1.08
Horizontal gene transfer converts non-toxigenic Clostridium difficile strains into toxin producers. Nat Commun (2013) 1.08
Using a dog's superior olfactory sensitivity to identify Clostridium difficile in stools and patients: proof of principle study. BMJ (2012) 1.08
Fecal microbiota transplantation in relapsing Clostridium difficile infection. Therap Adv Gastroenterol (2012) 1.07
Clostridium difficile MazF toxin exhibits selective, not global, mRNA cleavage. J Bacteriol (2012) 1.06
Structure-based modification of a Clostridium difficile-targeting endolysin affects activity and host range. J Bacteriol (2011) 1.05
Mechanism of action and epitopes of Clostridium difficile toxin B-neutralizing antibody bezlotoxumab revealed by X-ray crystallography. J Biol Chem (2014) 1.04
Antibiotics and the Human Gut Microbiome: Dysbioses and Accumulation of Resistances. Front Microbiol (2016) 1.03
Complete genome sequence of the Clostridium difficile laboratory strain 630Δerm reveals differences from strain 630, including translocation of the mobile element CTn5. BMC Genomics (2015) 1.03
Outcomes in patients tested for Clostridium difficile toxins. Diagn Microbiol Infect Dis (2012) 1.03
Probiotics and gastrointestinal disease: successes, problems and future prospects. Gut Pathog (2009) 1.03
A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice. J Infect Dis (2014) 1.02
A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile. Microbiology (2013) 1.02
The intestinal microbiota and susceptibility to infection in immunocompromised patients. Curr Opin Infect Dis (2013) 1.01
Recurrent Clostridium difficile infection: From colonization to cure. Anaerobe (2015) 1.00
Prevalence and pathogenicity of binary toxin-positive Clostridium difficile strains that do not produce toxins A and B. New Microbes New Infect (2014) 1.00
Evidence of in vivo prophage induction during Clostridium difficile infection. Appl Environ Microbiol (2012) 1.00
Automated detection of toxigenic Clostridium difficile in clinical samples: isothermal tcdB amplification coupled to array-based detection. J Clin Microbiol (2012) 1.00
High-throughput analysis of gene essentiality and sporulation in Clostridium difficile. MBio (2015) 0.99
Defining an allosteric circuit in the cysteine protease domain of Clostridium difficile toxins. Nat Struct Mol Biol (2011) 0.99
Whole genome sequencing reveals potential spread of Clostridium difficile between humans and farm animals in the Netherlands, 2002 to 2011. Euro Surveill (2014) 0.99
Emerging insights on intestinal dysbiosis during bacterial infections. Curr Opin Microbiol (2013) 0.99
Functional characterization of Clostridium difficile spore coat proteins. J Bacteriol (2013) 0.98
An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med (2005) 18.10
A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med (2005) 16.59
The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol (2008) 16.57
Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ (2004) 9.93
A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis (2007) 8.65
The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome. Nat Genet (2006) 8.02
Nosocomial acquisition of Clostridium difficile infection. N Engl J Med (1989) 7.72
Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis (2005) 7.16
Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect (2006) 6.90
Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med (2000) 6.24
Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis (2008) 6.21
Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature (1995) 6.08
Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis (2004) 5.67
Toxin B is essential for virulence of Clostridium difficile. Nature (2009) 5.49
Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun (1985) 5.44
A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol (2005) 5.26
Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg (2002) 4.91
Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ (2004) 4.88
Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol (2006) 4.87
A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J Clin Microbiol (1998) 4.79
Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis (2007) 4.77
Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet (2001) 4.59
Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis (2003) 4.28
The ClosTron: a universal gene knock-out system for the genus Clostridium. J Microbiol Methods (2007) 4.20
Diagnosis of Clostridium difficile infection by toxin detection kits: a systematic review. Lancet Infect Dis (2008) 4.07
Severe Clostridium difficile-associated disease in populations previously at low risk--four states, 2005. MMWR Morb Mortal Wkly Rep (2005) 3.60
Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol Lett (2000) 3.50
Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis (2008) 3.49
Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis (2008) 3.32
Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet (1998) 3.29
Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet (1983) 3.24
Comparison of real-time PCR for detection of the tcdC gene with four toxin immunoassays and culture in diagnosis of Clostridium difficile infection. J Clin Microbiol (2008) 3.21
Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg (2007) 3.08
A case-control study of community-associated Clostridium difficile infection. J Antimicrob Chemother (2008) 3.01
Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest (1995) 2.91
Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive "bundle" approach. Clin Infect Dis (2007) 2.90
Definition of the single integration site of the pathogenicity locus in Clostridium difficile. Gene (1996) 2.87
Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med (1999) 2.87
Large clostridial cytotoxins--a family of glycosyltransferases modifying small GTP-binding proteins. Trends Microbiol (1996) 2.85
A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Québec. Clin Infect Dis (2006) 2.85
Prevalence of PCR ribotypes among Clostridium difficile isolates from pigs, calves, and other species. J Clin Microbiol (2007) 2.76
Effective detection of toxigenic Clostridium difficile by a two-step algorithm including tests for antigen and cytotoxin. J Clin Microbiol (2006) 2.72
Comparison of the effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of Clostridium difficile infection. J Hosp Infect (2003) 2.68
Clostridium difficile: history of its role as an enteric pathogen and the current state of knowledge about the organism. Clin Infect Dis (1994) 2.51
Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology (2008) 2.50
tcdC genotypes associated with severe TcdC truncation in an epidemic clone and other strains of Clostridium difficile. J Clin Microbiol (2006) 2.49
Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. Euro Surveill (2008) 2.43
Production of a complete binary toxin (actin-specific ADP-ribosyltransferase) by Clostridium difficile CD196. Infect Immun (1997) 2.42
Does the nose know? The odiferous diagnosis of Clostridium difficile-associated diarrhea. Clin Infect Dis (2007) 2.42
Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the United States, 2001-2006. Pediatrics (2008) 2.31
Repression of Clostridium difficile toxin gene expression by CodY. Mol Microbiol (2007) 2.28
Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev (2005) 2.25
Transcription analysis of the genes tcdA-E of the pathogenicity locus of Clostridium difficile. Eur J Biochem (1997) 2.25
Clostridium difficile in retail meat products, USA, 2007. Emerg Infect Dis (2009) 2.24
Clostridium difficile in retail ground meat, Canada. Emerg Infect Dis (2007) 2.17
Hospital disinfectants and spore formation by Clostridium difficile. Lancet (2000) 2.13
Clostridium difficile PCR ribotypes in calves, Canada. Emerg Infect Dis (2006) 2.12
Auto-catalytic cleavage of Clostridium difficile toxins A and B depends on cysteine protease activity. J Biol Chem (2007) 2.11
Autocatalytic cleavage of Clostridium difficile toxin B. Nature (2007) 2.11
Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism. J Infect Dis (1989) 2.08
Efficacy of hospital cleaning agents and germicides against epidemic Clostridium difficile strains. Infect Control Hosp Epidemiol (2007) 2.06
Clostridium difficile toxin expression is inhibited by the novel regulator TcdC. Mol Microbiol (2007) 2.05
Heterogeneity of large clostridial toxins: importance of Clostridium difficile toxinotypes. FEMS Microbiol Rev (2008) 2.04
Clostridium difficile: an important pathogen of food animals. Anaerobe (2005) 2.01
Clostridium difficile surveillance trends, Saxony, Germany. Emerg Infect Dis (2008) 2.00
Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters. J Infect Dis (2006) 1.99
Toxinotype V Clostridium difficile in humans and food animals. Emerg Infect Dis (2008) 1.98
Surveillance for community-associated Clostridium difficile--Connecticut, 2006. MMWR Morb Mortal Wkly Rep (2008) 1.98
Epidemiology of community-acquired Clostridium difficile-associated diarrhea. J Infect Dis (1994) 1.96
Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother (2008) 1.91
Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection. CMAJ (2008) 1.91
Regulation of toxin synthesis in Clostridium difficile by an alternative RNA polymerase sigma factor. Proc Natl Acad Sci U S A (2001) 1.89
Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis (2007) 1.87
Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial Clostridium difficile diarrhea. Am J Med (1996) 1.84
Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother (2008) 1.84
Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. Antimicrob Agents Chemother (2008) 1.71
Relapse versus reinfection with Clostridium difficile. Epidemiol Infect (1991) 1.69
The distribution of Clostridium difficile in the environment of South Wales. J Med Microbiol (1996) 1.64
Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission. Am J Med (1990) 1.57
Is Clostridium difficile-associated infection a potentially zoonotic and foodborne disease? Clin Microbiol Infect (2007) 1.56
A novel toxin homologous to large clostridial cytotoxins found in culture supernatant of Clostridium perfringens type C. Microbiology (2007) 1.46
Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea. J Antimicrob Chemother (2004) 1.39
Metronidazole resistance in Clostridium difficile is heterogeneous. J Clin Microbiol (2008) 1.38
Evidence for holin function of tcdE gene in the pathogenicity of Clostridium difficile. J Med Microbiol (2001) 1.37
Identification of Clostridium difficile toxin B cardiotoxicity using a zebrafish embryo model of intoxication. Proc Natl Acad Sci U S A (2006) 1.35
Rho-glucosylating Clostridium difficile toxins A and B: new insights into structure and function. Glycobiology (2007) 1.35
Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection. J Antimicrob Chemother (2005) 1.34
Environmental control to reduce transmission of Clostridium difficile. Clin Infect Dis (2000) 1.34
Clostridium difficile toxin synthesis is negatively regulated by TcdC. J Med Microbiol (2008) 1.32
Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. CMAJ (2005) 1.31
gp96 is a human colonocyte plasma membrane binding protein for Clostridium difficile toxin A. Infect Immun (2008) 1.30
Clostridium difficile toxinotype V, ribotype 078, in animals and humans. J Clin Microbiol (2008) 1.30
Use of highly discriminatory fingerprinting to analyze clusters of Clostridium difficile infection cases due to epidemic ribotype 027 strains. J Clin Microbiol (2008) 1.30
Binary toxin production in Clostridium difficile is regulated by CdtR, a LytTR family response regulator. J Bacteriol (2007) 1.29
Revised nomenclature of Clostridium difficile toxins and associated genes. J Med Microbiol (2005) 1.28
The comparative pathology of Clostridium difficile-associated disease. Vet Pathol (2006) 1.26
Surface layer proteins from Clostridium difficile induce inflammatory and regulatory cytokines in human monocytes and dendritic cells. Microbes Infect (2006) 1.26
Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model. J Antimicrob Chemother (2008) 1.23
Proteomic analysis of cell surface proteins from Clostridium difficile. Proteomics (2005) 1.22
An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med (2005) 18.10
Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol (2010) 17.99
Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis (2006) 14.63
Burden of Clostridium difficile infection in the United States. N Engl J Med (2015) 8.17
Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med (2010) 7.37
Clostridium difficile infection in Europe: a hospital-based survey. Lancet (2011) 6.25
Toxin B is essential for virulence of Clostridium difficile. Nature (2009) 5.49
A pilot study of rapid benchtop sequencing of Staphylococcus aureus and Clostridium difficile for outbreak detection and surveillance. BMJ Open (2012) 3.93
Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium. Genome Biol (2009) 3.66
A mouse model of Clostridium difficile-associated disease. Gastroenterology (2008) 3.65
Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection. Lancet Infect Dis (2013) 3.56
Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis (2008) 3.32
Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology (2009) 3.29
Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis (2007) 3.15
Relationship between bacterial strain type, host biomarkers, and mortality in Clostridium difficile infection. Clin Infect Dis (2013) 3.15
Strategies to prevent central line-associated bloodstream infections in acute care hospitals. Infect Control Hosp Epidemiol (2008) 3.13
Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system. J Infect (2007) 2.84
Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med (2013) 2.78
Multilocus variable-number tandem-repeat analysis for investigation of Clostridium difficile transmission in Hospitals. J Clin Microbiol (2006) 2.52
In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother (2007) 2.43
A compendium of strategies to prevent healthcare-associated infections in acute care hospitals. Infect Control Hosp Epidemiol (2008) 2.32
Impact of strain type on detection of toxigenic Clostridium difficile: comparison of molecular diagnostic and enzyme immunoassay approaches. J Clin Microbiol (2010) 2.32
Strategies to prevent catheter-associated urinary tract infections in acute care hospitals. Infect Control Hosp Epidemiol (2008) 2.30
Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production. J Bacteriol (2010) 2.29
Strategies to prevent surgical site infections in acute care hospitals. Infect Control Hosp Epidemiol (2008) 2.22
Characterisation of Clostridium difficile hospital ward-based transmission using extensive epidemiological data and molecular typing. PLoS Med (2012) 2.12
Efficacy of hospital cleaning agents and germicides against epidemic Clostridium difficile strains. Infect Control Hosp Epidemiol (2007) 2.06
Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters. J Infect Dis (2006) 1.99
Toxinotype V Clostridium difficile in humans and food animals. Emerg Infect Dis (2008) 1.98
Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem. Clin Infect Dis (2004) 1.98
A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin Infect Dis (2004) 1.96
Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain. Clin Infect Dis (2012) 1.96
Assessment of best single sample for finding chlamydia in women with and without symptoms: a diagnostic test study. BMJ (2012) 1.93
Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother (2008) 1.91
Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine (2009) 1.85
Strategies to prevent clostridium difficile infections in acute care hospitals. Infect Control Hosp Epidemiol (2008) 1.84
Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother (2008) 1.84
Clostridium difficile: changing epidemiology and new treatment options. Curr Opin Infect Dis (2007) 1.84
Strategies to prevent ventilator-associated pneumonia in acute care hospitals. Infect Control Hosp Epidemiol (2008) 1.81
The potential for airborne dispersal of Clostridium difficile from symptomatic patients. Clin Infect Dis (2010) 1.70
Colonization for the prevention of Clostridium difficile disease in hamsters. J Infect Dis (2002) 1.68
CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother (2010) 1.67
Strategies to prevent transmission of methicillin-resistant Staphylococcus aureus in acute care hospitals. Infect Control Hosp Epidemiol (2008) 1.66
Comparison of strain typing results for Clostridium difficile isolates from North America. J Clin Microbiol (2011) 1.65
Clostridium difficile mixed infection and reinfection. J Clin Microbiol (2011) 1.59
Staphylococcus aureus and Clostridium difficile cause distinct pseudomembranous intestinal diseases. Clin Infect Dis (2004) 1.58
Characterization of the sporulation initiation pathway of Clostridium difficile and its role in toxin production. J Bacteriol (2009) 1.57
Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital. J Med Microbiol (2004) 1.52
Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis (2012) 1.51
Effectiveness of alcohol-based hand rubs for removal of Clostridium difficile spores from hands. Infect Control Hosp Epidemiol (2010) 1.51
Distribution of Clostridium difficile strains from a North American, European and Australian trial of treatment for C. difficile infections: 2005-2007. Anaerobe (2009) 1.47
Frequency of binary toxin genes among Clostridium difficile strains that do not produce large clostridial toxins. J Clin Microbiol (2003) 1.43
Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. Clin Infect Dis (2012) 1.42
Predictors of death after Clostridium difficile infection: a report on 128 strain-typed cases from a teaching hospital in the United Kingdom. Clin Infect Dis (2010) 1.41
Correlation between enterococcal biofilm formation in vitro and medical-device-related infection potential in vivo. J Med Microbiol (2003) 1.41
Molecular epidemiology of Clostridium difficile over the course of 10 years in a tertiary care hospital. Clin Infect Dis (2009) 1.39
Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin Infect Dis (2012) 1.38
Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model. J Antimicrob Chemother (2007) 1.35
Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection. J Antimicrob Chemother (2005) 1.34
Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection. Antimicrob Agents Chemother (2011) 1.33
NAP1 strain type predicts outcomes from Clostridium difficile infection. Clin Infect Dis (2014) 1.31
Infection of hamsters with historical and epidemic BI types of Clostridium difficile. J Infect Dis (2007) 1.29
Revised nomenclature of Clostridium difficile toxins and associated genes. J Med Microbiol (2005) 1.28
Risk factors for Clostridium difficile acquisition in infants: importance of study design. Clin Infect Dis (2013) 1.24
International typing study of toxin A-negative, toxin B-positive Clostridium difficile variants. J Clin Microbiol (2003) 1.23
Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model. J Antimicrob Chemother (2006) 1.23
Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model. J Antimicrob Chemother (2008) 1.23
Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model. J Antimicrob Chemother (2005) 1.23
Metronidazole for Clostridium difficile-associated disease: is it okay for Mom? Clin Infect Dis (2005) 1.21
Multilocus variable-number tandem-repeat analysis and multilocus sequence typing reveal genetic relationships among Clostridium difficile isolates genotyped by restriction endonuclease analysis. J Clin Microbiol (2009) 1.21
Recombinational switching of the Clostridium difficile S-layer and a novel glycosylation gene cluster revealed by large-scale whole-genome sequencing. J Infect Dis (2012) 1.21
Models for the study of Clostridium difficile infection. Gut Microbes (2012) 1.16
Evolutionary history of the Clostridium difficile pathogenicity locus. Genome Biol Evol (2014) 1.16
Whole genome sequencing and de novo assembly identifies Sydney-like variant noroviruses and recombinants during the winter 2012/2013 outbreak in England. Virol J (2013) 1.16
Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe (2009) 1.15
Molecular epidemiology of endemic Clostridium difficile infection and the significance of subtypes of the United Kingdom epidemic strain (PCR ribotype 1). J Clin Microbiol (2005) 1.15
Difference in the incidence of Clostridium difficile among patients infected with human immunodeficiency virus admitted to a public hospital and a private hospital. Infect Control Hosp Epidemiol (2002) 1.15
Clostridium difficile. Curr Opin Infect Dis (2002) 1.14
Predominance of a single restriction endonuclease analysis group with intrahospital subgroup diversity among Clostridium difficile isolates at two Chicago hospitals. Infect Control Hosp Epidemiol (2002) 1.14
Prevention of fatal Clostridium difficile-associated disease during continuous administration of clindamycin in hamsters. J Infect Dis (2003) 1.14
Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects. Antimicrob Agents Chemother (2012) 1.13
Effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut. J Antimicrob Chemother (2003) 1.11
International Clostridium difficile animal strain collection and large diversity of animal associated strains. BMC Microbiol (2014) 1.09
Pulsed-field gel electrophoresis can yield DNA fingerprints of degradation-susceptible Clostridium difficile strains. J Clin Microbiol (2002) 1.06
Onset of symptoms and time to diagnosis of Clostridium difficile-associated disease following discharge from an acute care hospital. Infect Control Hosp Epidemiol (2007) 1.03
Effect of nucleic acid amplification testing on population-based incidence rates of Clostridium difficile infection. Clin Infect Dis (2013) 1.03
Decreased effectiveness of metronidazole for the treatment of Clostridium difficile infection? Clin Infect Dis (2008) 1.03
Measurement of ampicillin, vancomycin, linezolid and gentamicin activity against enterococcal biofilms. J Antimicrob Chemother (2006) 1.01
Clostridium difficile infection among children across diverse US geographic locations. Pediatrics (2014) 1.01
An enhanced DNA fingerprinting service to investigate potential Clostridium difficile infection case clusters sharing the same PCR ribotype. J Clin Microbiol (2011) 1.00
Surface-layer protein A (SlpA) is a major contributor to host-cell adherence of Clostridium difficile. PLoS One (2013) 1.00
Does infection with specific Clostridium difficile strains or clades influence clinical outcome? Clin Infect Dis (2013) 0.99
Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model. J Antimicrob Chemother (2008) 0.99
New approach to the management of Clostridium difficile infection: colonisation with non-toxigenic C. difficile during daily ampicillin or ceftriaxone administration. Int J Antimicrob Agents (2009) 0.98
Fourteen-genome comparison identifies DNA markers for severe-disease-associated strains of Clostridium difficile. J Clin Microbiol (2011) 0.98
Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model. Antimicrob Agents Chemother (2008) 0.97
Antimicrobial-resistant pathogens in animals and man: prescribing, practices and policies. J Antimicrob Chemother (2010) 0.97